Magnetic-Field Induced Quantum Critical Point in YbRh2_2Si2_2

We report low-temperature calorimetric, magnetic and resistivity measurements on the antiferromagnetic (AF) heavy-fermion metal YbRh$_2$Si$_2$ (${T_N =}$ 70 mK) as a function of magnetic field $B$. While for fields exceeding the critical value ${B_{c0}}$ at which ${T_N\to0}$ the low temperature resistivity shows an ${AT^2}$ dependence, a ${1/(B-B_{c0})}$ divergence of ${A(B)}$ upon reducing $B$ to ${B_{c0}}$ suggests singular scattering at the whole Fermi surface and a divergence of the heavy quasiparticle mass. The observations are interpreted in terms of a new type of quantum critical point separating a weakly AF ordered from a weakly polarized heavy Landau-Fermi liquid state.Comment: accepted for publication in Phys. Rev. Let

Examine the species and beam-energy dependence of particle spectra using Tsallis Statistics

Tsallis Statistics was used to investigate the non-Boltzmann distribution of particle spectra and their dependence on particle species and beam energy in the relativistic heavy-ion collisions at SPS and RHIC. Produced particles are assumed to acquire radial flow and be of non-extensive statistics at freeze-out. J/psi and the particles containing strangeness were examined separately to study their radial flow and freeze-out. We found that the strange hadrons approach equilibrium quickly from peripheral to central A+A collisions and they tend to decouple earlier from the system than the light hadrons but with the same final radial flow. These results provide an alternative picture of freeze-outs: a thermalized system is produced at partonic phase; the hadronic scattering at later stage is not enough to maintain the system in equilibrium and does not increase the radial flow of the copiously produced light hadrons. The J/psi in Pb+Pb collisions at SPS is consistent with early decoupling and obtains little radial flow. The J/psi spectra at RHIC are also inconsistent with the bulk flow profile.Comment: 12 pages, 4 figures, added several references and some clarifications et

Analysis of Fourier transform valuation formulas and applications

The aim of this article is to provide a systematic analysis of the conditions such that Fourier transform valuation formulas are valid in a general framework; i.e. when the option has an arbitrary payoff function and depends on the path of the asset price process. An interplay between the conditions on the payoff function and the process arises naturally. We also extend these results to the multi-dimensional case, and discuss the calculation of Greeks by Fourier transform methods. As an application, we price options on the minimum of two assets in L\'evy and stochastic volatility models.Comment: 26 pages, 3 figures, to appear in Appl. Math. Financ

Future Experiments in Relativistic Heavy Ion Collisions

The measurements at RHIC have revealed a new state of matter, which needs to be further characterized in order to better understand its implications for the early evolution of the universe and QCD. I will show that, in the near future, complementary key measurements can be performed at RHIC, LHC, and FAIR. I will focus on results than can be obtained using identified particles, a probe which has been the basis for this conference over the past three decades. The sophisticated detectors, built and planned, for all three accelerator facilities enable us to measure leptons, photons, muons as well as hadrons and resonances of all flavors almost equally well, which makes these experiments unprecedented precision tools for the comprehensive understanding of the physics of the early universe.Comment: 10 pages, 4 figures, Proceedings for Summary Talk at SQM 2007, Levoca, Slovakia, June 24-29, 200

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

Background: The phase 2 BRIGHT AML 1003 trial evaluated efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized patients to receive glasdegib + LDAC (n = 78) or LDAC alone (n = 38). The rate of complete remission (CR) was 19.2% in the glasdegib + LDAC arm versus 2.6% in the LDAC arm (P = 0.015). Methods: This post hoc analysis determines whether the clinical benefits of glasdegib are restricted to patients who achieve CR, or if they extend to those who do not achieve CR. Results: In patients who did not achieve CR, the addition of glasdegib to LDAC improved overall survival (OS) versus LDAC alone (hazard ratio = 0.63 [95% confidence interval, 0.41-0.98]; P = 0.0182; median OS, 5.0 vs 4.1 months). Additionally, more patients receiving glasdegib + LDAC achieved durable recovery of absolute neutrophil count (≥ 1000/μl, 45.6% vs 35.5%), hemoglobin (≥ 9 g/dl, 54.4% vs 38.7%), and platelets (≥ 100,000/μl, 29.8% vs 9.7%). Transfusion independence was achieved by 15.0% and 2.9% of patients receiving glasdegib + LDAC and LDAC alone, respectively. Conclusions: Collectively, these data suggest that there are clinical benefits with glasdegib in the absence of CR. Trial registration: ClinicalTrials.gov NCT01546038 (March 7, 2012

III.7 Planets orbiting stars more massive than the Sun

This book is dedicated to all the people interested in the CoRoT mission and the beautiful data that were delivered during its six year duration. Either amateurs, professional, young or senior researchers, they will find treasures not only at the time of this publication but also in the future twenty or thirty years. It presents the data in their final version, explains how they have been obtained, how to handle them, describes the tools necessary to understand them, and where to find them. It also highlights the most striking first results obtained up to now. CoRoT has opened several unexpected directions of research and certainly new ones still to be discovered